Treatment of Primary Sclerosing Cholangitis with Persistently Elevated ALP or GGT
In patients with Primary Sclerosing Cholangitis (PSC) who have persistently elevated alkaline phosphatase (ALP) or gamma-glutamyl transferase (GGT), a structured, evidence-based treatment approach targets meaningful biochemical improvement within a defined timeframe.
Clinical Scenario
This protocol addresses PSC patients with persistently elevated ALP or GGT — biochemical markers that guide treatment decisions and serve as primary endpoints for response assessment.
Treatment Approach
Ursodeoxycholic acid (UDCA) may be considered as a treatment option in this setting. Continuation of therapy depends on achieving defined biochemical response criteria — the complete eligibility criteria, dosing, and decision algorithm are available in the full protocol.
Clinical Goals
The key targets are meaningful reduction or normalization of ALP within 12 months of treatment. In adults, specific ALP thresholds determine response; in children, GGT is the primary marker, with defined reduction targets guiding ongoing management decisions.
References
DOI: 10.1002/hep.32771
In patients not eligible or interested in clinical trials with persistently elevated ALP or GGT, UDCA 13–23 mg/kg/day can be considered for treatment and continued if there is a meaningful reduction or normalization in ALP (GGT in children) and/or symptoms improve with 12 months of treatment.
However, recent data in adults have shown that meaningful reductions in ALP have been associated with significantly better outcomes, including (1) reduction of ALP to < 1.5 × ULN, (2) 40% reduction or normalization of ALP, and (3) normalization of ALP.
In children, a 75% reduction in GGT or a GGT < 50 IU was associated with the best outcomes.